Drug Discovery
ByGSK Reports Full-Year 2025 Results with Strategic Portfolio Focus
GSK today reported its full-year performance for 2025 and outlined its strategic approach to long-term growth across vaccines,…
Roche Reports Full-Year 2025 Results and Provides Strategic Portfolio Insights
Roche today announced its full-year 2025 performance and outlined its strategic positioning across key therapeutic areas. Roche maintained…
Top 10 Pharma Brands of 2025 — Sales Performance, Company Strategy & Market Outlook
The pharmaceutical market in 2025 was defined by high-value specialty brands delivering breakthrough outcomes in oncology, metabolic disease,…
Big Pharma Accelerates Shift to Off-the-Shelf Cell Therapy with Strategic Acquisitions
The global biopharmaceutical industry is entering a new phase in cell therapy innovation, marked by significant investments in…
Is Pierre Fabre’s US Cell‑Therapy Comeback Bid a Signal of Regulatory Reset for Rare Diseases?
Pierre Fabre is reviving its US cell‑therapy ambitions, seeking FDA re‑approval for Ebvallo after the agency initially rejected its submission.…
Is Roche’s $480M Bet Making South Korea Asia’s Next Biopharma Powerhouse?
Roche’s $480M Bet on South Korea Signals a Strategic Pivot to Asia’s AI–Oncology Powerhouse Roche has committed $480 million to…
